By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Nostrum Pharmaceuticals 



Basingstoke      United Kingdom
Phone: n/a Fax:


SEARCH JOBS


Industry
Pharmaceutical

Segment
Research





Company News
Nostrum Pharmaceuticals Licenses Clinical Development and Worldwide Commercialization Rights From IMTECH, India for Novel, Next-Generation Thrombolytics With Clot Specific Activation and Re-occlusion Prevention Properties 11/29/2010 6:44:21 AM
Nostrum Pharmaceuticals Obtains Worldwide Licensing Rights From IMTECH for Clinical Development of the Small Molecule Caerulomycin and Its Proprietary Derivatives for Their Novel Indication of Immunosuppression 2/24/2009 9:43:15 AM
Nostrum Pharmaceuticals Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein 4/22/2008 8:28:12 AM
Synovics Pharmaceuticals, Inc. (SYVC.OB) Announces the Settlement of all Legal Proceedings with Nostrum Pharmaceuticals., Dr. Nirmal Mulye and Anil Anand 8/7/2007 1:37:05 PM
Nostrum Pharmaceuticals Obtains Worldwide Licensing Rights From Institute of Microbial Technology (IMTECH) For Clinical Development Of A Novel Clot Busting Therapeutic Protein 7/28/2006 10:17:28 AM
Shire Pharmaceuticals Group plc (SHPGY) Release: CARBATROL(R) Paragraph IV Litigation Update10/19/2005 5:11:39 PM
Elite Pharmaceuticals, Inc. (ELI) Announces End Of Negotiations With Nostrum Pharmaceuticals10/19/2005 5:11:09 PM
Nostrum Pharmaceuticals Confident Regarding Outcome Of Shire Laboratories' Carbamazepine ER Litigation 10/19/2005 5:09:02 PM
//-->